You are here: Welcome » pharmaceutical_companies » Merck

Differences

This shows you the differences between two versions of the page.

Link to this comparison view

Both sides previous revisionPrevious revision
Next revision
Previous revision
Both sides next revision
pharmaceutical_companies:merck [2022/06/14 02:17]
liam
pharmaceutical_companies:merck [2023/10/02 18:18] (current)
pamela
Line 7: Line 7:
 ===== History ===== ===== History =====
  
-May 2002, The [[:Bill & Melinda Gates Foundation]] purchased stock in Merck.((Bank, D., & Buckman, R. (2002, May 17). //Gates Foundation buys stakes in drug makers.// Wall Street Journal. https://archive.ph/XP9QA))+In May 2002, The [[:Bill & Melinda Gates Foundation]] purchased stock in Merck.((Bank, D., & Buckman, R. (2002, May 17). //Gates Foundation buys stakes in drug makers.// Wall Street Journal. https://archive.ph/XP9QA))
  
 ===== Affiliations ===== ===== Affiliations =====
Line 18: Line 18:
  
 Merck is a contributing member of [[:AcademyHealth]].((//Current Organizational Members.// AcademyHealth. Retrieved May 8, 2022, from https://archive.ph/CjV83)) Merck is a contributing member of [[:AcademyHealth]].((//Current Organizational Members.// AcademyHealth. Retrieved May 8, 2022, from https://archive.ph/CjV83))
 +
 +==== Campaign to Censor & Smear MD VIOXX Critics ====
 +{{ :pharmaceutical_companies:merck_md_hit_list_vioxx.png?400|}}
 +CBS News By Jim Edwards MoneyWatch May 6, 2009,
 +
 +Merck made a "hit list" of doctors who criticized Vioxx, according to testimony in a Vioxx class action case in Australia. The list, emailed between Merck employees, contained doctors' names with the labels "neutralise," "neutralised" or "discredit" next to them.((https://web.archive.org/web/20140822200310/https://www.cbsnews.com/news/merck-created-hit-list-to-destroy-neutralize-or-discredit-dissenting-doctors/))
 +
  
 ===== COVID-19 ===== ===== COVID-19 =====
Line 35: Line 42:
 Antiviral Molnupiravir Reduced the Risk of Hospitalization or Death by Approximately 50 Percent Compared to Placebo for Patients Antiviral Molnupiravir Reduced the Risk of Hospitalization or Death by Approximately 50 Percent Compared to Placebo for Patients
 with Mild or Moderate COVID-19 in Positive Interim Analysis of Phase 3 Study.// Merck. Retrieved December 5, 2021, from https://archive.ph/Ov4Cg)) ((Halford, B., Howes, L., & Satyanarayana, M. (2021, October 1). //Molnupiravir reduces risk of hospitalization and death in patients with mild to moderate COVID-19.// Chemical & Engineering News; American Chemical Society. https://archive.ph/8sJfE)) with Mild or Moderate COVID-19 in Positive Interim Analysis of Phase 3 Study.// Merck. Retrieved December 5, 2021, from https://archive.ph/Ov4Cg)) ((Halford, B., Howes, L., & Satyanarayana, M. (2021, October 1). //Molnupiravir reduces risk of hospitalization and death in patients with mild to moderate COVID-19.// Chemical & Engineering News; American Chemical Society. https://archive.ph/8sJfE))
 +
 +==== Africa Vaccine Campaigns ====
 +
 +Merck, Gates Foundation Give $60 Million to Fight HIV/AIDS in Botswana
 +August 25, 2010 
 +
 +
 +
 +The Merck Company and [[:Bill & Melinda Gates Foundation]] have announced a joint five-year, $60 million contribution to a public-private partnership working to fight HIV/AIDS in Botswana.
 +
 +Each foundation will contribute $30 million to the [[:African Comprehensive HIV/AIDS Partnerships]] (ACHAP) to support new and ongoing efforts to meet the needs of the 137,000 Batswana (people from Botswana) living with HIV. ACHAP's second-phase initiatives will include efforts focused on HIV prevention, the treatment of HIV patients who also have tuberculosis, and program sustainability to help Botswana become self-sustaining in its efforts to combat the HIV epidemic among its citizens. With the funding, the two foundations have contributed a total of $166.5 million to ACHAP, and Merck continues to donate HIV medicines to the effort.
 +
 +Between 2001 and 2007, ACHAP, which is led by the government of Botswana, helped prevent an estimated 53,000 HIV-related deaths. Today, some 90 percent of Batswana living with HIV receive treatment, compared to less than 5 percent when the program began nine years ago.
 +
 +"For nearly ten years, Merck has been a partner in helping the government of Botswana save the lives of thousands of people living with HIV and AIDS, and we are confident our new funding will continue to contribute to the well-being of the country," said Merck chairman and CEO [[:Richard T. Clark]]. "This collaboration is a great success story on many levels and has become a model for many countries both on and off the African continent." ((https://web.archive.org/web/20141103064347/https://philanthropynewsdigest.org/news/merck-gates-foundation-give-60-million-to-fight-hiv-aids-in-botswana))
 +
Back to top